agilon health (NYSE:AGL – Get Rating) and Lisata Therapeutics (NASDAQ:LSTA – Get Rating) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.
Risk & Volatility
agilon health has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.Get agilon health alerts:
This table compares agilon health and Lisata Therapeutics' net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and EarningsThis table compares agilon health and Lisata Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|agilon health||$1.83 billion||3.59||-$406.49 million||($0.26)||-61.50|
|Lisata Therapeutics||N/A||N/A||-$27.47 million||($12.23)||-0.20|
Lisata Therapeutics has lower revenue, but higher earnings than agilon health. agilon health is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations for agilon health and Lisata Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
agilon health presently has a consensus price target of $28.38, indicating a potential upside of 77.45%. Lisata Therapeutics has a consensus price target of $15.00, indicating a potential upside of 527.62%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lisata Therapeutics is more favorable than agilon health.
Insider and Institutional Ownership
6.0% of Lisata Therapeutics shares are held by institutional investors. 3.3% of agilon health shares are held by insiders. Comparatively, 2.2% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Lisata Therapeutics beats agilon health on 7 of the 13 factors compared between the two stocks.
About agilon health
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.
About Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Receive News & Ratings for agilon health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for agilon health and related companies with MarketBeat.com's FREE daily email newsletter.